<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01422421</url>
  </required_header>
  <id_info>
    <org_study_id>H21-rinsho shiken ippan-017</org_study_id>
    <nct_id>NCT01422421</nct_id>
  </id_info>
  <brief_title>Intensive Blood Pressure and LDL Lowering in Diabetic Patients With Coronary Artery Disease</brief_title>
  <official_title>Intensive Blood Pressure and LDL Lowering for Better Survival and Cardiovascular Outcome in Diabetic Patients With Coronary Artery Disease: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeshi Morimoto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of the Ryukyus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyoto University, Graduate School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intensive blood pressure and low density
      lipoprotein (LDL) cholesterol lowering could improve survival and cardiovascular outcome in
      Japanese diabetic patients with coronary artery disease and history of acute coronary
      syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prevalence of type 2 diabetes in Asia seems to be almost epidemic and establishment of
      preventive strategy against macrovascular as well as microvascular diseases are warranted
      because of higher cardiovascular risk in diabetic patients even without history of
      atherosclerotic cardiovascular diseases. Benefit of lowering low density lipoprotein (LDL)
      cholesterol down to 70 mg/ml in Caucasian patients with coronary artery disease (CAD) has
      been well established but not in Asian patients with lower risk of myocardial infarction and
      higher stroke risk. Intensive lowering blood pressure for cardiovascular outcome in diabetic
      patients and patients with CAD has been recommended in several guidelines without firm
      evidence. Risk and benefit of intensive blood pressure and LDL control should be evaluated in
      Japanese diabetic CAD patients by pragmatic randomized controlled trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite endpoint</measure>
    <time_frame>3 years</time_frame>
    <description>composite endpoint consisting of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke and unstable angina requiring hospital administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>important secondary composite endpoint</measure>
    <time_frame>3 years</time_frame>
    <description>composite endpoint consisting of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, unstable angina requiring hospital administration, and admission for heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>3 years</time_frame>
    <description>death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>3 years</time_frame>
    <description>non fatal myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>3 years</time_frame>
    <description>non fatal stroke excluding transient ischemic attack</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>end stage renal disease</measure>
    <time_frame>3 years</time_frame>
    <description>end stage renal disease needs kidney transplantation or hemodialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peripheral artery disease</measure>
    <time_frame>3 years</time_frame>
    <description>peripheral artery disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new onset or deterioration of heart failure</measure>
    <time_frame>3 years</time_frame>
    <description>new onset or deterioration of heart failure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Hypertension</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>intensive control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>systolic blood pressure less than 120mmHg and LDL cholesterol within 70- 85mg/dl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intensive control</intervention_name>
    <description>use any medication to achieve systolic blood pressure less than 120mmHg and LDL cholesterol within 70-85mg/dl</description>
    <arm_group_label>intensive control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard control</intervention_name>
    <description>use any medication to achieve systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl</description>
    <arm_group_label>standard control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetic patients with coronary artery disease and history of acute coronary
             syndrome

          -  Patients whose blood pressure and LDL cholesterol levels are above values recommended
             by the current guideline

        Exclusion Criteria:

          -  Patients who have active malignant tumor

          -  Patients who are on hemodialysis due to end stage kidney disease

          -  Patients whom statins are contraindicated

          -  Patients who had acute coronary syndrome or stroke within 3 months

          -  Patients who are pregnant or on breast feeding

          -  Patients whose physicians deem that attending this trial is contraindicated or
             inappropriate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shinichiro Ueda, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Clinical Pharmacology and Therapeutics, University of the Ryukyus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shinichiro Ueda, MD, PhD</last_name>
    <phone>+81-98-895-1195</phone>
    <email>blessyou@med.u-ryukyu.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Takeshi Morimoto, MD, PhD</last_name>
    <email>ceo@icekyoto.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital, University of the Ryukyus</name>
      <address>
        <city>Nishihara</city>
        <state>Okinawa</state>
        <zip>903-0215</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shinichiro Ueda, MD, PhD</last_name>
      <phone>81-98-895-1195</phone>
      <email>blessyou@med.u-ryukyu.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Uru Nezu, MD, PhD</last_name>
      <phone>81-98-895-1195</phone>
      <email>amadeus@med.u-ryukyu.ac.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Shinichiro Ueda, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saga University Hospital</name>
      <address>
        <city>Saga</city>
        <zip>849-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koichi Node, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Koichi Node, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2011</study_first_submitted>
  <study_first_submitted_qc>August 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2011</study_first_posted>
  <last_update_submitted>March 25, 2018</last_update_submitted>
  <last_update_submitted_qc>March 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kyoto University, Graduate School of Medicine</investigator_affiliation>
    <investigator_full_name>Takeshi Morimoto</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>hypertension</keyword>
  <keyword>dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

